Key result
Metformin significantly improved vascular endothelial function compared to pioglitazone in patients with type 2 diabetes, achieving higher vascular dilation rates during reactive hyperemia (11.3% vs 9.2%, p=0.026).
Why the study?
Does metformin improve vascular endothelial function more than pioglitazone in patients with type 2 diabetes mellitus?
RCT (n=93)
Randomly assigned
No
Does metformin improve vascular endothelial function more than pioglitazone in patients with type 2 diabetes mellitus?
Absolute Event Rate: 11.3% vs 9.2%
p-value: p=0.026
Metformin is more effective than pioglitazone in improving vascular endothelial function and reducing BMI in patients with type 2 diabetes mellitus.
Metformin may be prioritized over pioglitazone for endothelial function in T2DM; extends comparative vascular data from randomized evidence.
The aim of the present study was to examine the effect of metformin on endothelial function in patients with type 2 diabetes mellitus (T2DM). In total, 93 patients with T2DM and dissatisfactory glycemic control were randomly assigned to the metformin and pioglitazone groups and changes in vascular endothelial function were subsequently observed. Blood sugar levels and the insulin resistance (IR) index of the patients prior to treatment were lower than those following 12 months of treatment. In addition, fasting and postprandial insulin levels and the insulin function index were higher compared with those obtained following 12 months of treatment (P<0.05). Following 12 months of treatment, the body mass index (BMI) in the metformin group was lower than that in the pioglitazone group (P<0.05). Vascular endothelial function had improved in the groups following 12 months of treatment, when compared with the levels prior to treatment (P<0.05). Following 12 months of treatment, endothelial function in the metformin group had improved markedly compared with that in the pioglitazone group (P<0.05). Therefore, the administration of metformin and pioglitazone in patients with T2DM may improve insulin function, reduce the role of IR and improve endothelial function. Metformin is more successful than pioglitazone in reducing BMI and improving endothelial function.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2014) conducted an RCT in Type 2 diabetes mellitus (n=93). Metformin vs. Pioglitazone (15 mg once/day) was evaluated on Vascular dilation rate during reactive hyperemia at 12 months (p=0.026). Metformin significantly improved vascular endothelial function compared to pioglitazone in patients with type 2 diabetes, achieving higher vascular dilation rates during reactive hyperemia (11.3% vs 9.2%, p=0.026).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: